A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer

Overview of attention for article published in BMC Cancer, July 2007

Altmetric Badge

Mentioned by

patent: 1 patent

Citations

dimensions_citation: 68 Dimensions

Readers on

mendeley: 51 Mendeley
connotea: 1 Connotea

Summary Patents Dimensions citations

So far, Altmetric has seen 1 patent that references this research output.

TARGETING THE EGFR-SGLT1 INTERACTION FOR CANCER THERAPY

Application WO-2014182955-A2

World Intellectual Property Organisation (WIPO)

This page shows the most recent patents that mention this research output.

Click here to find out how to access more activity.